The iPhone maker's shares [rallied for a second day]( ...

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the ...

AM ET, the S&P 500 added 0.6%, the Dow Jones Industrial Average was up 0.4%, and the Nasdaq Composite was 1.1% higher.

FRANKFURT: European shares logged their biggest daily rise in over two weeks on Thursday, boosted by financial ...

Analysts expect the market to remain range-bound, tracking developments around US-Russia peace talks, India’s response to US ...

Australian pharmaceutical companies retreated in morning trade after shares in US pharma giant Eli Lilly dived 14% overnight, due disappointing data on its new oral weight loss pill.